Hematology Practice Questions

Q: Sideroblastic anemia is caused due to:

Iron. Sideroblastic anemia is a group of blood disorders characterized by the body's inability to incorporate iron into hemoglobin, despite having adequate iron stores. **Why Iron is the Correct Answer:** The hallmark of this condition is the presence of **ringed sideroblasts** in the bone marrow. These are erythroblasts with iron-loaded mitochondria arranged in a necklace-like pattern around the nucleus. The underlying pathology involves a defect in **heme synthesis** (specifically the protoporphyrin pathway). While iron is available, it cannot be utilized to form heme, leading to iron sequestration within the mitochondria [2]. Therefore, the anemia is fundamentally a disorder of **iron utilization**. **Analysis of Incorrect Options:** * **Lead (B):** While lead poisoning is a classic cause of *acquired* sideroblastic anemia (by inhibiting enzymes like ALA dehydratase and ferrochelatase), it is a secondary cause. In the context of this specific question format, "Iron" refers to the pathophysiological substrate trapped in the mitochondria. * **Mercury (A) and Arsenic (C):** These heavy metals are toxic to various organ systems but are not primary or common causes of sideroblastic anemia. Arsenic poisoning typically presents with pancytopenia or basophilic stippling, but not ringed sideroblasts. **NEET-PG High-Yield Pearls:** * **Diagnostic Gold Standard:** Bone marrow examination with **Prussian Blue stain** showing ≥15% ringed sideroblasts. * **Genetic Cause:** Most common hereditary form is X-linked, due to a mutation in the **ALAS2 gene**. * **Acquired Causes:** Alcohol (most common), Lead, Isoniazid (Vitamin B6 antagonist), and Myelodysplastic Syndrome (MDS-RS). * **Treatment:** Pyridoxine (Vitamin B6) is the first-line treatment for hereditary and isoniazid-induced cases. * **Lab Findings:** Increased Serum Iron, Increased Ferritin, and Increased Transferrin Saturation (Iron Overload state) [1].

Q: Which genetic abnormality is associated with the worst prognosis in Chronic Lymphocytic Leukemia (CLL)?

17p Deletion. **Explanation:** The prognosis of Chronic Lymphocytic Leukemia (CLL) is heavily influenced by cytogenetic abnormalities identified via FISH (Fluorescence In Situ Hybridization). **1. Why 17p Deletion is the Correct Answer:** The **17p deletion** involves the loss of the **TP53 gene**, which is located on the short arm of chromosome 17. TP53 is a critical tumor suppressor gene responsible for DNA repair and apoptosis. Its absence leads to resistance against standard chemotherapy (like Fludarabine) and rapid disease progression. Patients with this mutation have the shortest median survival and are often candidates for targeted therapies like Ibrutinib (BTK inhibitors) or Venetoclax (BCL-2 inhibitors) rather than traditional chemo-immunotherapy. **2. Analysis of Incorrect Options:** * **13q Deletion (Option D):** This is the **most common** cytogenetic abnormality in CLL. When it occurs as an isolated finding, it is associated with the **best (most favorable) prognosis** and long survival [1]. * **11q Deletion (Option A):** Associated with extensive lymphadenopathy and an aggressive clinical course, but the prognosis is generally better than 17p deletion. It involves the loss of the ATM gene. * **12q Trisomy (Option B):** Associated with an intermediate prognosis. **High-Yield Clinical Pearls for NEET-PG:** * **Döhner’s Hierarchy of Prognosis (Best to Worst):** 13q deletion > Normal cytogenetics > Trisomy 12 > 11q deletion > 17p deletion. * **ZAP-70 and CD38:** High expression of these markers indicates a **poor prognosis**. * **IgVH Mutation Status:** *Unmutated* IgVH signifies a poor prognosis, whereas *mutated* IgVH signifies a favorable prognosis. * **Smudge Cells:** A classic peripheral smear finding in CLL (crushed lymphocytes). **Note on Survival:** Survival in CLL is heavily influenced by specific prognostic features and the ability to tolerate intensive therapy [1].

Q: A 35-year-old female evaluated for anemia has a dry marrow tap and a peripheral smear showing tear drop cells. What is the most likely diagnosis?

Primary Myelofibrosis. The clinical presentation of a **dry tap** (unsuccessful bone marrow aspiration) combined with **teardrop cells (dacrocytes)** on a peripheral smear is the classic hallmark of **Primary Myelofibrosis (PMF)** [1]. 1. **Why Primary Myelofibrosis is correct:** PMF is a myeloproliferative neoplasm characterized by extensive collagen deposition in the bone marrow (fibrosis). This fibrosis prevents the aspiration of marrow contents, resulting in a **"dry tap."** [1] As red blood cells are forced to squeeze through the fibrotic marrow and exit via the splenic sinusoids, they become physically distorted, taking on a **teardrop shape** [1]. This process is often accompanied by extramedullary hematopoiesis and a leukoerythroblastic blood picture [1]. 2. **Why other options are incorrect:** * **Acute Myeloid Leukemia (AML):** While AML can occasionally cause a dry tap due to hypercellularity (packed marrow), the peripheral smear typically shows **blasts** and Auer rods, not predominant teardrop cells. * **Hodgkin’S Disease:** This primarily involves lymph nodes. While it can involve the marrow in late stages, it is not the classic cause of the dacrocyte/dry tap triad. * **Polycythemia Vera (PV):** PV is characterized by an increased red cell mass (high Hb/Hct). While PV can progress to a "spent phase" (Post-PV Myelofibrosis) which mimics PMF, PMF is the primary diagnosis associated with this specific presentation in a 35-year-old female. **High-Yield Clinical Pearls for NEET-PG:** * **Dacrocytes (Teardrop cells):** Think "Myelofibrosis" or "Thalassemia" [1]. * **Dry Tap Differential:** Myelofibrosis, Hairy Cell Leukemia, Aplastic Anemia, and occasionally packed marrow in Leukemias. * **Genetic Marker:** ~50-60% of PMF cases are positive for the **JAK2 V617F** mutation [1]. * **Splenomegaly:** Massive splenomegaly is a common physical finding in PMF due to extramedullary hematopoiesis [1].

Q: Which of the following is most likely to cause a hypochromic microcytic anemia?

Iron deficiency anemia. **Explanation:** **Iron Deficiency Anemia (IDA)** is the most common cause of **microcytic hypochromic anemia** worldwide [1], [4]. The underlying mechanism involves a decrease in hemoglobin synthesis. Hemoglobin is composed of heme (iron + protoporphyrin) and globin. When iron is deficient, heme production drops, leading to fewer hemoglobin molecules per cell. Consequently, erythrocytes undergo extra divisions to maintain concentration, resulting in smaller cells (**Microcytic: MCV 100 fL) [2]. Folate is essential for DNA synthesis; its deficiency leads to impaired nuclear maturation while cytoplasmic growth continues, resulting in large, oval red cells and hypersegmented neutrophils. * **Hereditary spherocytosis:** This is a normocytic or mildly microcytic hemolytic anemia. Crucially, it is **hyperchromic** (elevated MCHC) because the loss of membrane surface area causes the cell to become spherical and densely packed with hemoglobin. * **Sickle cell anemia:** This is typically a **Normocytic normochromic** anemia. While it is a qualitative hemoglobinopathy (HbS), the size and color of the cells are generally normal unless there is a co-existing iron deficiency or alpha-thalassemia. **High-Yield Clinical Pearls for NEET-PG:** * **Differential Diagnosis for Microcytic Anemia (TAIL):** **T**halassemia, **A**nemia of Chronic Disease (late stage), **I**ron Deficiency, **L**ead poisoning/Sideroblastic anemia [1]. * **Best Screening Test for IDA:** Serum Ferritin (decreased). * **Earliest Sign of Response to Iron Therapy:** Reticulocytosis (usually within 5–7 days). * **Mentzer Index:** MCV/RBC count. If ** 13**, suspect Iron Deficiency Anemia.

Q: Which of the following drugs is NOT used for the management of multiple myeloma?

Hydroxyurea. **Explanation:** The management of Multiple Myeloma (MM) has evolved significantly, focusing on proteasome inhibitors, immunomodulatory drugs (IMiDs), and alkylating agents [1]. **Why Hydroxyurea is the correct answer:** **Hydroxyurea** is a ribonucleotide reductase inhibitor primarily used in the management of **Myeloproliferative Neoplasms (MPNs)** such as Polycythemia Vera, Essential Thrombocythemia, and Chronic Myeloid Leukemia (CML), as well as in Sickle Cell Anemia to increase HbF levels. It is **not** a standard treatment for Multiple Myeloma, as it lacks significant efficacy against malignant plasma cells. **Analysis of other options:** * **Bortezomib:** A first-line **Proteasome Inhibitor**. It induces apoptosis in plasma cells by inhibiting the 26S proteasome, leading to the accumulation of misfolded proteins. It is a cornerstone of induction therapy (e.g., VRd regimen) [1]. * **Melphalan:** A potent **Alkylating Agent** (nitrogen mustard derivative). It is historically significant in MM treatment and remains the gold standard conditioning agent used before **Autologous Stem Cell Transplantation (ASCT)** [1]. * **Cyclophosphamide:** Another **Alkylating Agent** frequently used in MM, especially in patients with renal impairment or as part of salvage regimens (e.g., CyBorD). **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for MM features:** **CRAB** (Calcium elevation, Renal insufficiency, Anemia, Bone lesions) [1]. * **Drug of Choice for Induction:** Bortezomib + Lenalidomide + Dexamethasone (VRd) [1]. * **Newer Agents:** Daratumumab (Anti-CD38 monoclonal antibody) is now frequently added to frontline therapy. * **Investigation of Choice:** Whole-body low-dose CT (WBLDCT) or MRI is preferred over the traditional skeletal survey for detecting lytic lesions [1].

Q: Which of the following are complications of long-term hemophilia?

Joint deformity. **Explanation:** **Hemophilia** (A or B) is characterized by a deficiency in clotting factors VIII or IX, leading to a failure in the secondary hemostatic pathway. **Why Option A is Correct:** The hallmark of long-term, poorly controlled hemophilia is **Hemophilic Arthropathy**. Recurrent bleeding into the joint spaces (**hemarthrosis**), most commonly the knees, elbows, and ankles, leads to synovial hypertrophy and chronic inflammation [1]. Over time, the iron (hemosiderin) deposits from the blood damage the articular cartilage, resulting in joint space narrowing, subchondral cysts, and eventually permanent **joint deformity** and ankylosis [1]. **Analysis of Incorrect Options:** * **B. Transfusion-transmitted disease:** While historically a major complication (HIV, Hepatitis B/C) due to plasma-derived factors, the advent of recombinant factors and rigorous screening has significantly reduced this risk in modern practice [2]. It is considered a potential risk of therapy, not a direct pathological complication of the disease itself. * **C. Renal calculi:** There is no direct pathophysiological link between hemophilia and the formation of kidney stones. * **D. Severe iron deficiency anemia:** Hemophilic bleeds are typically internal (joints/muscles). Since the iron remains within the body (sequestered in tissues), it is recycled by macrophages [1]. Therefore, iron deficiency is rare unless there is significant external blood loss (e.g., GI bleed). **High-Yield Clinical Pearls for NEET-PG:** * **Target Joint:** Defined as a single joint that has had ≥3 spontaneous bleeds within a 6-month period. * **Earliest Sign:** The earliest radiographic sign of hemophilic arthropathy is soft tissue swelling; the most specific late sign is the widening of the intercondylar notch of the femur. * **Management:** Primary prophylaxis with factor replacement is the gold standard to prevent arthropathy [2]. Avoid NSAIDs and IM injections.

Q: In contrast to iron deficiency anemia, what is the typical change in TIBC in anemia of chronic disease?

Decreases. **Explanation:** The key to distinguishing Anemia of Chronic Disease (ACD) from Iron Deficiency Anemia (IDA) lies in the body's handling of iron stores. In ACD, the primary driver is inflammation, which leads to an increase in **Hepcidin** [1]. Hepcidin inhibits ferroportin, causing iron to be trapped inside macrophages and hepatocytes [2]. **Why TIBC Decreases (Correct Answer):** Total Iron Binding Capacity (TIBC) is an indirect measure of **Transferrin** levels. In states of chronic inflammation, Transferrin acts as a **negative acute-phase reactant**. The body downregulates transferrin production to "hide" iron from potential pathogens and because there is already sufficient (though sequestered) internal iron. Therefore, TIBC decreases in ACD. **Why Other Options are Incorrect:** * **Increases (Option B):** This is the hallmark of **Iron Deficiency Anemia**. In IDA, the liver increases transferrin production to maximize the transport of any available iron, leading to a high TIBC [3]. * **Normal (Option C):** While TIBC can occasionally be in the low-normal range in early ACD, the "typical" and classic board-exam finding is a decrease. **High-Yield Clinical Pearls for NEET-PG:** * **Serum Ferritin:** This is the most useful test to differentiate the two. Ferritin is **increased** in ACD (positive acute-phase reactant) but **decreased** in IDA [3]. * **Transferrin Saturation:** Decreased in both, but usually more severely low in IDA (<15%) [3]. * **Soluble Transferrin Receptor (sTfR):** Normal in ACD but **elevated** in IDA [3]. This is a high-yield marker when both conditions coexist. * **Gold Standard:** Bone marrow aspiration showing increased iron in macrophages (Prussian blue stain) confirms ACD [2].

Q: Which of the following is NOT seen in Paroxysmal Nocturnal Hemoglobinuria?

Decreased LDH. **Explanation:** **Paroxysmal Nocturnal Hemoglobinuria (PNH)** is an acquired clonal hematopoietic stem cell disorder caused by a mutation in the **PIGA gene**. This leads to a deficiency of GPI-anchored proteins, specifically **CD55 (DAF)** and **CD59 (MIRL)**, which normally protect red blood cells from complement-mediated lysis [1]. **Why "Decreased LDH" is the correct answer:** PNH is characterized by **intravascular hemolysis** [1]. When red cells rupture within the circulation, lactate dehydrogenase (LDH), an intracellular enzyme, is released into the plasma. Therefore, **elevated LDH** (often >5-10 times the upper limit of normal) is a hallmark of PNH, not decreased LDH. **Analysis of incorrect options:** * **Thrombosis:** This is the most common cause of death in PNH. Hemolysis releases free hemoglobin, which scavenges Nitric Oxide (NO), leading to smooth muscle dystonia and a pro-thrombotic state. Common sites include hepatic veins (Budd-Chiari syndrome) and cerebral sinuses. * **Hemosiderinuria:** Chronic intravascular hemolysis leads to the filtration of hemoglobin by the kidneys. Iron is deposited in the renal tubular cells as hemosiderin, which is then sloughed into the urine. This often leads to iron deficiency. * **Thrombocytopenia:** PNH is a stem cell disorder. It frequently overlaps with **Aplastic Anemia**, and the defective clone can affect all cell lines, leading to pancytopenia (anemia, leucopenia, and thrombocytopenia). **High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard Diagnosis:** Flow Cytometry (shows absence of CD55 and CD59 on RBCs and WBCs). * **Classic Triad:** Hemolytic anemia, Pancytopenia, and Thrombosis. * **Treatment:** **Eculizumab** (a monoclonal antibody against Complement C5) is the drug of choice. * **Screening Test:** FLAER (Fluorescent Proaerolysin) assay is highly sensitive for detecting the PNH clone.

Question 1

Sideroblastic anemia is caused due to:

Accepted Answer

Iron

Answer

Mercury

Answer

Lead

Answer

Arsenic

Question 2

Which genetic abnormality is associated with the worst prognosis in Chronic Lymphocytic Leukemia (CLL)?

Accepted Answer

17p Deletion

Answer

11q Deletion

Answer

12q Trisomy

Answer

13q Deletion

Question 3

A 35-year-old female evaluated for anemia has a dry marrow tap and a peripheral smear showing tear drop cells. What is the most likely diagnosis?

Accepted Answer

Primary Myelofibrosis

Answer

Acute myeloid leukemia

Answer

Hodgkin's Disease

Answer

Polycythemia vera

Question 4

Which of the following conditions is a common cause of iron deficiency anemia?

Accepted Answer

Chronic renal failure (CRF)

Answer

Billroth II operation

Answer

Hookworm infestation

Answer

Celiac sprue

Question 5

Which of the following is most likely to cause a hypochromic microcytic anemia?

Accepted Answer

Iron deficiency anemia

Answer

Folate deficiency

Answer

Hereditary spherocytosis

Answer

Sickle cell anemia

Question 6

Which of the following drugs is NOT used for the management of multiple myeloma?

Accepted Answer

Hydroxyurea

Answer

Bortezomib

Answer

Melphalan

Answer

Cyclophosphamide

Question 7

Which of the following are complications of long-term hemophilia?

Accepted Answer

Joint deformity

Answer

Transfusion transmitted disease

Answer

Renal calculi

Answer

Severe iron deficiency anemia

Question 8

In contrast to iron deficiency anemia, what is the typical change in TIBC in anemia of chronic disease?

Accepted Answer

Decreases

Answer

Increases

Answer

Normal

Answer

None of the above

Question 9

Which of the following are characteristic features of secondary polycythemia?

Accepted Answer

Pruritus

Answer

Hypertension

Answer

Arterial oxygen tension < 92%

Answer

Increased red cell mass

Question 10

Which of the following is NOT seen in Paroxysmal Nocturnal Hemoglobinuria?

Accepted Answer

Decreased LDH

Answer

Thrombosis

Answer

Hemosiderinuria

Answer

Thrombocytopenia

Hematology — MCQs

Hematology — MCQs

On this page

Practice by Chapter

Want unlimited practice?